This inventor holds 1 USPTO granted patent. Top assignee: Roche Tcrc Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Peter N. Morcos and His Patent Work.
Introduction
Peter N. Morcos is an inventor associated with Marlboro, New Jersey, and Roche TCRC Inc. His patent work includes an invention concerning treatment with an anti-CD20/anti-CD3 bispecific antibody.
Latest Patents
Morcos is named on 1 patent: “Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibody.” The patent addresses dosing for treatment using a bispecific antibody that targets CD20 and CD3.
Career Highlights
Morcos’s listed patent reflects work in the development of antibody-based treatments. He is associated with Roche TCRC Inc., a company involved in biotechnology and pharmaceutical research.
Collaborations
The patent lists Martin Weisser and David Carlile among Morcos’s coworkers, reflecting a collaborative effort on the invention.
Conclusion
Peter N. Morcos’s patent work is focused on antibody-based treatment, with his listed invention addressing dosing for an anti-CD20/anti-CD3 bispecific antibody.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile